New Weight-Loss Drug Reduces Body Weight in Monkeys, Mice
November 14, 2011 11:42 AM
Anti-obesity drug Adipotide
(Source: University of Texas M. D. Anderson Cancer Center)
The new drug, called Adipotide, attacks white adipose tissue under the skin and around the abdomen
Researchers at the University of Texas MD Anderson Cancer Center have developed a drug that assaults the blood supply of fat cells and led to weight loss in obese rhesus monkeys.
Renata Pasqualini, Ph.D., co-senior author of the study and professor in MD Anderson's David H. Koch Center for Applied Research for Genitourinary Cancers, along with Wadih Arap, M.D., co-senior author of the study and a professor in the Koch Center, and Kirstin Barnhart, D.V.M., Ph.D., veterinary clinical pathologist at MD Anderson's Keeling Center for Comparative Medicine and Research, have created a new weight-loss drug that could potentially reduce accumulated
white fat in humans
Currently, weight-loss drugs work to suppress the appetite or increase metabolism in order to
, but harmful side effects come with the use of such drugs.
Now, Pasqualini and Arap have designed a new drug called Adipotide, which attacks white adipose tissue. This tissue is an unhealthy kind of fat that accumulates around the abdomen and under the skin. Adipotide contains a homing agent that attaches to a protein on the surface of blood vessels that support the fat. A synthetic peptide then triggers cell death, and with a lack of blood supply, the fat cells are reabsorbed.
The drug was used in mice models and rhesus monkey models. Adipotide was able to decrease abdominal circumference, body mass index (BMI) and body fat.
According to the study, the obese mice lost about 30 percent of their body weight while on Adipotide. The rhesus monkeys in the study, which were "spontaneously" obese due to overeating and a lack of physical activity, had a 27 percent decrease in abdominal fat levels. The drug reduced the weight of rhesus monkeys by 11 percent in just one month.
The rhesus monkeys, in addition to
, had other health problems associated with their obesity such as metabolic syndrome. This can lead to type 2 diabetes and cardiovascular disease. But those treated with Adipotide used about 50 percent less insulin.
The research team used Magnetic Resonance Imaging (MRI) to gauge abdominal body fat, which discovered the reduction in abdominal fat levels.
According to the study, monkeys were alert and acted normally during treatment. This showed that the usual side effects of weight-loss drugs, such as loss of appetite and nausea, were not present while using Adipotide. However, Barnhart noted side effects in the kidneys, but the effect was "dose-dependent, predictable and reversible."
In a separate study to test for the drug's effects in non-obese monkeys, lean monkeys did not lose weight, which shows that the drug only acts in obese subjects.
The next step will be a clinical trial for obese prostate cancer patients, where these patients will receive daily injections of Adipotide for 28 days. The team has targeted prostate cancer patients because current treatments can lead to weight gain, and weight gain has caused problems with arthritis. This then leads to less activity, and more weight gain.
"The question is, will their prostate cancer become better if we can reduce their body weight and the associated health risks," said Arap.
was published in
"People Don't Respect Confidentiality in This Industry" -- Sony Computer Entertainment of America President and CEO Jack Tretton
Gene "KLF14" Acts as Switch for Type 2 Diabetes, Obesity
May 16, 2011, 11:54 AM
Turning White Fat into Brown Fat Could Curb Obesity in Humans
May 5, 2011, 3:50 PM
World Has Grown Much, Much Fatter: Obesity Doubles in 30 Years
February 4, 2011, 11:03 AM
Cyber Hackers Threaten Security of Lifesaving Medical Devices
October 19, 2016, 8:09 AM
Innovative Neurotechnology in Sound Therapy Reduces High Blood Pressure and Migraines
October 16, 2016, 5:00 AM
Researchers Move Closer to Breakthrough Gene Therapy to Cure Sickle Cell
October 14, 2016, 5:00 AM
Keytruda: A breakthrough treatment to increase survival rates for lung cancer patients
October 12, 2016, 5:00 AM
CDC Warning about Record High Increases in 2016 for Polio-like Illness causing Paralysis
October 9, 2016, 5:00 AM
Hypertension in children impacts cognitive performance
October 5, 2016, 5:00 AM
Most Popular Articles
Car Insurance - The Hidden Discriminatory Practise
October 18, 2016, 5:00 AM
Problems with Windows 10 – Update Now
October 15, 2016, 7:30 AM
Is Razer Blade Stealth Laptop For You?
October 16, 2016, 5:00 AM
Tesla Event Pushed to Wednesday
October 17, 2016, 5:00 AM
Smart Technology Mood Collar To Understand Your Dog’s Emotions
October 17, 2016, 5:00 AM
Latest Blog Posts
Mac Users, Try this if Your Mac is Infected?
Oct 23, 2016, 7:00 AM
Tips to Prevent Smartphones From Overheating:
Oct 22, 2016, 5:00 AM
Nasa Flies Drones at Nevada Airport
Oct 21, 2016, 8:21 AM
T-Mobile Data Problems
Oct 20, 2016, 10:17 AM
Annoying Apple Watch Problems and How to Fix Them
Oct 20, 2016, 5:00 AM
Your Mail May Soon Be Delivered By Robot
Oct 19, 2016, 9:34 AM
2018 Jeep Wrangler Prototype Sells At Junkyard
Oct 18, 2016, 5:00 AM
Samsung Shines with Gold Edition Tablet
Oct 17, 2016, 9:24 AM
Tesla Hints Mysterious Product Debut for October 17th
Oct 16, 2016, 10:14 AM
Samsung Galaxy Note 7 Phones on US flights
Oct 15, 2016, 5:00 AM
Comcast Fined $2.3 Million For Unconfirmed Services Charged To Customers
Oct 14, 2016, 5:00 AM
“American singer / songwriter “Bob Dylan is awarded 2016 Nobel Prize in Literature.
Oct 13, 2016, 10:33 AM
Battery Defect in Medical Device
Oct 12, 2016, 5:00 AM
IBM Bolsters Social Services Sector With Technology Grants
Oct 11, 2016, 5:00 AM
Scientists Sound Alarm on Climate but US Still Toys With Skepticism
Oct 10, 2016, 5:00 AM
IMEX America Trade Show
Oct 9, 2016, 10:00 AM
Phone Wars – Google VS Samsung Free Gifts on Purchase
Oct 6, 2016, 5:00 AM
Member of Parliament’s opposition car exploded in Tbilist capital of Georgia
Oct 5, 2016, 2:52 PM
More Blog Posts
Copyright 2016 DailyTech LLC. -
Terms, Conditions & Privacy Information